BiotechTube

Dalteparin sodium + Placebo

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Thromboembolism

Conditions

Thromboembolism, Deep Vein Thrombosis, Dalteparin

Trial Timeline

Apr 1, 2003 → Dec 1, 2003

NCT ID
NCT00655122

About Dalteparin sodium + Placebo

Dalteparin sodium + Placebo is a approved stage product being developed by Pfizer for Thromboembolism. The current trial status is terminated. This product is registered under clinical trial identifier NCT00655122. Target conditions include Thromboembolism, Deep Vein Thrombosis, Dalteparin.

What happened to similar drugs?

2 of 20 similar drugs in Thromboembolism were approved

Approved (2) Terminated (4) Active (15)
🔄Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3
🔄Edoxaban + Standard of CareDaiichi SankyoPhase 3
🔄15mg DU-176b + 30mg DU-176b + FondaparinuxDaiichi SankyoPhase 3
🔄DU-176b (edoxaban) + Enoxaparin sodium 20mgDaiichi SankyoPhase 3
🔄edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
🔄edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarinDaiichi SankyoPhase 3
🔄YM150Astellas PharmaPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00655122ApprovedTerminated

Competing Products

20 competing products in Thromboembolism

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
26
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)Daiichi SankyoPhase 2
35
Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3
40
EdoxabanDaiichi SankyoPre-clinical
26
Edoxaban + Standard of CareDaiichi SankyoPhase 3
40
DU-176b + DU-176b + DU-176b + DU-176b + PlaceboDaiichi SankyoPhase 2
35
15mg DU-176b + 30mg DU-176b + FondaparinuxDaiichi SankyoPhase 3
40
DU-176b (edoxaban) + Enoxaparin sodium 20mgDaiichi SankyoPhase 3
40
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
40
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarinDaiichi SankyoPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150 + enoxaparinAstellas PharmaPhase 2
35
YM150Astellas PharmaPhase 3
40
YM150 + enoxaparinAstellas PharmaPhase 2/3
38
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
38
YM150Astellas PharmaPhase 3
40
YM150Astellas PharmaPhase 2
35
YM150Astellas PharmaPhase 3
40
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
38
Dalteparin sodium + Dalteparin sodium/aspirinEisaiPre-clinical
26